Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

In this case report, a patient with alopecia areata-associated nail changes experienced normalization of nail appearance and texture after 11 months of treatment with baricitinib, suggesting that the drug may be an effective option for similar cases, although further research is needed.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study found that when applied for 24 hours, a polyherbal formulation made from Ficus religiosa and Abrus precatorious promoted more significant hair growth in Male Wistar rats than Minoxidil and the control group, and the extracts also exhibited notable antibacterial activities.

In this study, black wolfberry ferment was found to promote hair regrowth in mice with androgenetic alopecia by increasing hair weight, follicle count, and skin thickness, potentially through PI3K/AKT, NF-kappa B, and MAPK signaling pathways.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

Proper shaving techniques and specific topical treatments can help manage pseudofolliculitis barbae.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

In this study, applying water extracts of liquorice at a concentration of 2.5% to male rabbits led to the best rate of hair growth at 2.19 cm over 35 days, while a 5% concentration resulted in the greatest hair weight at 0.12 grams.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This study found that topical application of Russelia equisetiformis methanol extract significantly increased hair growth in albino Wistar rats, potentially due to its triterpene and flavonoid content.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.

In this study, 1% procyanidin B-2 tonic significantly increased the number of total and terminal hairs on the scalp of male participants compared to a placebo after 6 months of use.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This article discusses the cosmetic potential of grapefruit, particularly its skin conditioning and hair growth benefits, but reports no new research findings.

This study provides a detailed profile of bioactive polyphenols in various parts of the baobab fruit, highlighting its potential as a health-promoting food or supplement.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study reports that activating the bitter taste receptor TAS2R4 with rebaudioside A can inhibit hair growth in human scalp hair follicles by promoting catagen through TGF-β pathway activation.